Report

This report summarizes the TB Elimination Alliance's (TEA) activities and outcomes from 2019 to 2024.

This report provides an early analysis of cases of tuberculosis (TB) disease reported to the Centers for Disease Control and Prevention (CDC) during 2024 as compared with previous years. CDC used U.S. Census Bureau population estimates to calculate rates (cases per 100,000 persons) of TB disease.

This report outlines the National Institute of Allergy and Infectious Diseases' (NIAID) updated strategic plan to combat tuberculosis. It focuses on four key priorities: enhancing fundamental knowledge of TB, advancing diagnostic research, accelerating vaccine development, and supporting strategies to treat and prevent TB.

This webpage presents data on newly reported chronic hepatitis C cases in Alaska from 2016 to 2023. It underscores the importance of continued hepatitis C surveillance to guide targeted testing and treatment efforts toward disease elimination.

This report outlines progress toward eliminating mother-to-child transmission of hepatitis B virus (HBV) in the Americas from 2012 to 2022. It highlights improvements in vaccination coverage, including birth doses, but also notes coverage declines in some countries, which could hinder elimination goals. The report emphasizes the need for maintaining high vaccination rates, expanding hepatitis B testing for pregnant women, and ensuring timely treatment for newborns.

This report outlines the progress made toward the elimination of mother-to-child transmission of hepatitis B virus in the Region of the Americas from 2012 to 2022. It highlights key strategies, achievements, and challenges in achieving the goal of reducing the transmission rates, providing a comprehensive overview of regional efforts to combat this public health issue.

This report proposes policies for expanding access to hepatitis C (HCV) testing and treatment in United States jails and prisons. The report's policy recommendations draw principally from settlement agreements, judicial opinions, and other filings in those cases, supplemented by current medical guidance and input from public health experts, medical professionals, and advocates.

This report lays out the required sections that must be included in a state’s Section 1115 Demonstration application and identifies where and how a state can be explicit about its intent to address the health care needs of individuals with hepatitis C as part of its Justice-Involved Reentry Initiative.

This report discusses how SARS-CoV-2, the virus that causes COVID-19, rapidly evolves in people with advanced HIV due to weakened immune responses. This prolonged viral replication can lead to the emergence of new variants, highlighting the importance of HIV treatment and COVID-19 prevention efforts in immunocompromised populations.

This report provides an update on national progress in meeting the goals of the National HIV/AIDS Strategy (2022-2025) based on the most current available data and also highlights some recent federal efforts to implement the Strategy.